<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28462" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Diabetic Retinopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shukla</surname>
            <given-names>Unnati V.</given-names>
          </name>
          <aff>Centre for Sight new delhi</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tripathy</surname>
            <given-names>Koushik</given-names>
          </name>
          <aff>ASG Eye Hospital, BT Road, Kolkata, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Unnati Shukla declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Koushik Tripathy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28462.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Diabetic retinopathy is the leading cause of visual loss in adults of the working-age group in the western population. It is the most common microvascular complication of diabetes mellitus. Diabetic retinopathy may lead to vision-threatening damage to the retina, eventually leading to blindness. Strict glycemic control, early detection, and appropriate management is the key to halting the progression of the disease. This activity reviews the pathogenesis, diagnosis, and management of diabetic retinopathy and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of diabetic retinopathy.</p></list-item><list-item><p>Summarize the clinical features that will present in an evaluation of diabetic retinopathy.</p></list-item><list-item><p>Review the management and prognosis of diabetic retinopathy.</p></list-item><list-item><p>Highlight the role of interprofessional collaboration in improving the outcomes in patients with diabetic retinopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28462&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28462">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28462.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Diabetic retinopathy (DR) is a microvascular disorder occurring due to the long-term effects of diabetes mellitus. Diabetic retinopathy may lead to vision-threatening damage to the retina, eventually leading to blindness. It is the most common cause of severe vision loss in adults of working age groups in the western world.<xref ref-type="bibr" rid="article-28462.r1">[1]</xref>&#x000a0;Early detection and timely intervention are the keys to avoiding blindness due to diabetic retinopathy. The number of patients with diabetic retinopathy in America is estimated to reach 16.0 million by 2050, with vision-threatening complications affecting around 3.4 million of them.<xref ref-type="bibr" rid="article-28462.r2">[2]</xref> The usefulness of strict glycemic control was clearly seen in clinical trials like the UK Prospective Diabetes Study (UKPDS) and Diabetes Control and Complication Trial (DCCT).<xref ref-type="bibr" rid="article-28462.r3">[3]</xref><xref ref-type="bibr" rid="article-28462.r4">[4]</xref>&#x000a0;</p>
        <p>Uncontrolled diabetes can lead to many ocular disorders like cataracts, glaucoma, ocular surface disorders, recurrent stye, non-arteritic anterior ischemic optic neuropathy, diabetic papillopathy, and diabetic retinopathy. Diabetic retinopathy may lead to vision-threatening damage to the retina, eventually leading to blindness; it is the most common and severe ocular complication.<xref ref-type="bibr" rid="article-28462.r5">[5]</xref><xref ref-type="bibr" rid="article-28462.r6">[6]</xref><xref ref-type="bibr" rid="article-28462.r7">[7]</xref>&#x000a0;Poor glycemic control, uncontrolled hypertension, dyslipidemia, nephropathy, male sex, and obesity are associated with worsening diabetic retinopathy.<xref ref-type="bibr" rid="article-28462.r8">[8]</xref><xref ref-type="bibr" rid="article-28462.r9">[9]</xref>&#x000a0;Typical fundus features of diabetic retinopathy include microaneurysms, hard exudates, macular edema (diabetic macular edema or DME), and new vessels (in proliferative DR or PDR). The management options include strict control of the systemic conditions,&#x000a0;intravitreal pharmacotherapy, and laser photocoagulation. With early diagnosis and prompt management, good final visual acuity&#x000a0;may be achieved in most patients with DR.</p>
      </sec>
      <sec id="article-28462.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Diabetic retinopathy affects people&#x000a0;with&#x000a0;diagnosed or undiagnosed diabetes mellitus. The propensity to develop diabetic retinopathy is directly proportional to the patient's age and duration of diabetes, as well as poor glycemic control and fluctuating blood pressure levels.<xref ref-type="bibr" rid="article-28462.r10">[10]</xref></p>
        <p>Risk factors for diabetic retinopathy&#x000a0;can be classified into:</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-modifiable
<list list-type="bullet"><list-item><p>Puberty</p></list-item><list-item><p>Pregnancy</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Modifiable
<list list-type="bullet"><list-item><p>Hypertension</p></list-item><list-item><p>Obesity</p></list-item><list-item><p>Dyslipidemia</p></list-item><list-item><p>Poor glycemic control</p></list-item><list-item><p>Nephropathy</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Newer risk factors
<list list-type="bullet"><list-item><p>Inflammation</p></list-item><list-item><p>Apolipoprotein</p></list-item><list-item><p>Hormonal influence - leptin and adiponectin</p></list-item><list-item><p>Vitamin D</p></list-item><list-item><p>Oxidative stress</p></list-item><list-item><p>Genetic factors<xref ref-type="bibr" rid="article-28462.r11">[11]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28462.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Diabetic retinopathy is one of the major neurovascular complications of diabetes and is a leading cause of blindness in adults of the working-age group. According to the recent epidemiological data shared by the American Academy of Ophthalmology, the global burden of diabetes mellitus is 387 million, which is estimated to increase to 592 million by 2035.&#x000a0;Ninety-three million people are globally affected by diabetic retinopathy. Prevalence of diabetic retinopathy is 77.3% in type 1 diabetes patients and 25.1% in type 2 diabetes patients, out of which approximately 25% to 30% are expected to develop vision-threatening diabetic macular edema.<xref ref-type="bibr" rid="article-28462.r12">[12]</xref>&#x000a0;Between 5%&#x000a0;and 8% of patients with diabetic retinopathy need laser treatment.<xref ref-type="bibr" rid="article-28462.r13">[13]</xref>&#x000a0;As many as 5% of patients will require vitrectomy surgery.<xref ref-type="bibr" rid="article-28462.r14">[14]</xref></p>
      </sec>
      <sec id="article-28462.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p><bold>Chronic hyperglycemia</bold> is considered to be the primary pathogenic agent in DR (as described by UKPDS and DCCT).<xref ref-type="bibr" rid="article-28462.r4">[4]</xref><xref ref-type="bibr" rid="article-28462.r3">[3]</xref>&#x000a0;Hyperglycemia leads to the activation of alternative pathways of glucose metabolism,&#x000a0;including the polyol pathway. The oxidative stress, protein kinase C activation, and non-enzymatic protein glycation lead to advanced glycation endproducts (AGEs). The result of these alternative pathways is the activation of cytokines along with the growth factors and&#x000a0;vascular endothelial dysfunction, which eventually leads to increased vascular permeability and microvascular occlusion. Retinal ischemia, which occurs as a consequence of microvascular occlusion, leads to the formation of IRMA (intraretinal microvascular abnormalities) and neovascularization.<xref ref-type="bibr" rid="article-28462.r15">[15]</xref><xref ref-type="bibr" rid="article-28462.r16">[16]</xref>&#x000a0;</p>
        <p>In the polyol pathway, glucose is reduced to sorbitol by the aldose reductase enzyme. The impermeability of sorbitol leads to its accumulation in all retinal cells leading to osmotic damage to the cells. Also, the use of NADPH (reduced nicotinamide adenine dinucleotide phosphate) during the reduction process leads to further oxidative damage.</p>
        <p><bold>Oxidative stress</bold>&#x000a0;results from increased levels of reactive oxygen species (ROS), leading to cell and tissue damage.</p>
        <p>Protein kinase C is involved in signal transduction. Its activation leads to basement membrane alterations and vascular changes like increased vascular permeability, the release of angiogenic growth factors, vascular stasis, and capillary occlusion.&#x000a0;</p>
        <p>In non-enzymatic protein glycation, reducing sugars react with free amino acids of nucleic acids, proteins, and lipids leading to the formation of advanced glycation endproducts responsible for the alterations in extracellular matrix proteins.</p>
        <p>The morphological changes seen in small retinal vessels in DR include early loss of pericytes, basement membrane thickening, loss of endothelial cells, increased vascular permeability, platelet aggregation, leukostasis, and capillary dropout.<xref ref-type="bibr" rid="article-28462.r17">[17]</xref><xref ref-type="bibr" rid="article-28462.r18">[18]</xref>&#x000a0;</p>
        <p>Diabetic retinopathy does not only affect the microvessels of the retina but also the&#x000a0;M&#x000fc;ller cells, which are the primary glial cells of the retina. The functions of M&#x000fc;ller cells are maintaining the structural integrity of the retina, regulation of the blood-retinal barrier and retinal blood flow, uptake and recycling of various neurotransmitters, retinoic acid compounds, and ions (such as potassium), regulation of metabolism and supply of nutrients to the retina.<xref ref-type="bibr" rid="article-28462.r19">[19]</xref></p>
        <p>In diabetes, there is downregulation of the Kir 4.1 channel because of which there is continued potassium uptake leading to swelling of M&#x000fc;ller cells, which leads to Muller cell dysfunction.<xref ref-type="bibr" rid="article-28462.r20">[20]</xref>&#x000a0;Fluid accumulation inside the Muller cells is responsible for DME.<xref ref-type="bibr" rid="article-28462.r21">[21]</xref><xref ref-type="bibr" rid="article-28462.r20">[20]</xref>&#x000a0;Early inner retinal neuronal and&#x000a0;M&#x000fc;ller cell involvement may be noted in preclinical and early clinical DR.<xref ref-type="bibr" rid="article-28462.r22">[22]</xref>&#x000a0;Activation of&#x000a0;M&#x000fc;ller cells and overexpression of&#x000a0;glial fibrillary acidic protein (GFAP) are noted in DR.<xref ref-type="bibr" rid="article-28462.r19">[19]</xref></p>
        <p>Hyperglycemia leads to the release of growth factors and cytokines/chemokines.<xref ref-type="bibr" rid="article-28462.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Growth factors:
<list list-type="bullet"><list-item><p>Vascular endothelial growth factor (VEGF)</p></list-item><list-item><p>Pigment epithelium-derived factor (PEDF)<xref ref-type="bibr" rid="article-28462.r24">[24]</xref></p></list-item><list-item><p>Platelet-derived growth factor(PDGF)<xref ref-type="bibr" rid="article-28462.r25">[25]</xref></p></list-item><list-item><p>Basic fibroblast growth factor ( bFGF or FGF2)</p></list-item><list-item><p>Insulin-like growth factor (IGF)</p></list-item><list-item><p>Hepatocyte growth factor/scatter factor (HGF/SF)</p></list-item><list-item><p>Placental growth factor (PIGF)<xref ref-type="bibr" rid="article-28462.r26">[26]</xref></p></list-item><list-item><p>Erythropoietin</p></list-item><list-item><p>Angiopoietin-2</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Cytokines and chemokines:
<list list-type="bullet"><list-item><p>Interleukin-1&#x003b2; (IL-&#x003b2;)</p></list-item><list-item><p>Interleukin-6 (IL-6)</p></list-item><list-item><p>Tumor necrosis factor-&#x003b1; (TNF-&#x003b1;)</p></list-item><list-item><p>Chemokine ligand-2 (CCL2)<xref ref-type="bibr" rid="article-28462.r27">[27]</xref><xref ref-type="bibr" rid="article-28462.r28">[28]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28462.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histologically diabetic retinopathy presents&#x000a0;with microangiopathy associated with vascular changes like focal capillary closure, dilatation of venules, hyalinization of arterioles, and capillary changes like basement membrane thickening, pericyte degeneration, and focal outpouchings (microaneurysms). Capillary closure leads to cotton wool spots and ischemic areas, leading to the development of IRMA (intraretinal microvascular abnormalities) and neovascularization, followed by fibrosis and contracture of the retina.<xref ref-type="bibr" rid="article-28462.r29">[29]</xref><xref ref-type="bibr" rid="article-28462.r30">[30]</xref>&#x000a0;</p>
        <p>In diabetic retinopathy, the uptake of glutamate by M&#x000fc;ller cells decreases, leading to glutamate toxicity.<xref ref-type="bibr" rid="article-28462.r31">[31]</xref>&#x000a0;Also, potassium conductance is decreased in proliferative diabetic retinopathy.<xref ref-type="bibr" rid="article-28462.r32">[32]</xref></p>
      </sec>
      <sec id="article-28462.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Proper history taking should be done. This includes the duration of diabetes, type of diabetes mellitus, past glycemic control (HbA1C), medication, and associated systemic&#x000a0;disorders&#x000a0;like obesity, kidney disease, hypertension, pregnancy, dyslipidemia, and nephropathy.</p>
        <p>Patients might be asymptomatic in the early stages and might be discovered incidentally on fundus examination. As the disease progresses,&#x000a0;the symptoms&#x000a0;include blurred vision, distorted vision, floaters, and partial or total vision loss.&#x000a0;</p>
        <p>Signs seen in diabetic retinopathy on fundus examination include:</p>
        <p>
<bold>Microaneurysms</bold>
</p>
        <p>Microaneuryms are the earliest clinically detectable lesions.<xref ref-type="bibr" rid="article-28462.r33">[33]</xref> Microaneurysms initially appear temporal to the fovea and may disappear with time. The&#x000a0;diameter of a microaneurysm is 15- 60 &#x000b5;m (less than 125&#x000a0;&#x000b5;m). Microaneurysms with a diameter of less than 30 &#x000b5;m may not be detectable clinically.<xref ref-type="bibr" rid="article-28462.r34">[34]</xref> The features of microaneurysms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Focal saccular dilatation of the capillary wall&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Location in the inner nuclear layer</p>
          </list-item>
          <list-item>
            <p>Clinically identified by ophthalmoscopy as tiny, round, red dots with a sharp regular margin</p>
          </list-item>
        </list>
        <p>Microaneurysms are differentiated from dot hemorrhages by FFA (fundus fluorescein angiogram),&#x000a0;wherein microaneurysms show tiny hyperfluorescent points, whereas dot hemorrhages show blocked fluorescence. Dot hemorrhages are clinically larger and may have an irregular margin.<xref ref-type="bibr" rid="article-28462.r35">[35]</xref></p>
        <p>
<bold>Hemorrhages</bold>
</p>
        <p>Weakened capillary wall ruptures lead to intraretinal dot hemorrhages.&#x000a0;Superficial or flame-shaped hemorrhages arise from the precapillary arterioles located in the retinal nerve fiber layer. Deep hemorrhages or dot and blot hemorrhages are located in the inner nuclear and outer plexiform layers of the retina.&#x000a0;</p>
        <p>
<bold>Hard Exudates</bold>
</p>
        <p>They are composed of lipoprotein and lipid-filled macrophages located in the outer plexiform layer. They develop at the junction of the edematous and non-edematous retina. The hard exudates typically form a circinate ring around a leaking microaneurysm.</p>
        <p>
<bold>Cotton Wool Spots/Soft Exudates</bold>
</p>
        <p>They are located in the retinal nerve fiber layer (axoplasmic debris) and represent focal infarcts of the precapillary arterioles.</p>
        <p>
<bold>IRMA (intraretinal microvascular abnormalities)</bold>
</p>
        <p>IRMAs are intercommunications between retinal arteriole and venules, which bypass the capillaries and are seen near the areas of capillary closure. IRMAs are intraretinal in location, do not cross the major vessels, and do not leak on fluorescein angiography.</p>
        <p>
<bold>Venous Changes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dilatation</p>
          </list-item>
          <list-item>
            <p>Looping</p>
          </list-item>
          <list-item>
            <p>Beading</p>
          </list-item>
          <list-item>
            <p>Sausage-like segmentation</p>
          </list-item>
        </list>
        <p>
<bold>Arterial Changes</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Peripheral narrowing</p>
          </list-item>
          <list-item>
            <p>Silver-wiring</p>
          </list-item>
          <list-item>
            <p>Obliteration</p>
          </list-item>
        </list>
        <p>
<bold>Neovascularization</bold>
</p>
        <p>Neovascularization (new vessels) at the disc (NVD) is defined as neovascularization at or within one disc diameter of the optic disc. Neovascularization elsewhere (NVE) is defined as a new vessel away from one disc diameter of the optic disc. Neovascularization of Iris (NVI) is a marker of poor prognosis and is associated with the propensity to develop neovascular glaucoma.</p>
        <p>
<bold>Early Treatment Diabetic Retinopathy Study (ETDRS) Classification&#x000a0;</bold>
</p>
        <p>
<bold>Nonproliferative&#x000a0;Diabetic Retinopathy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>No retinopathy</bold>: No retinal lesions</p>
          </list-item>
          <list-item>
            <p><bold>Very mild NPDR</bold>: Microaneurysms only</p>
          </list-item>
          <list-item>
            <p><bold>Mild NPDR</bold>: A few microaneurysms, retinal hemorrhages &#x00026; hard exudates</p>
          </list-item>
          <list-item>
            <p><bold>Moderate NPDR</bold>: Retinal hemorrhages (about 20 medium-large per quadrant) in 1-3 quadrant + cotton wool spots (between the grades mild and severe NPDR)</p>
          </list-item>
          <list-item>
            <p><bold>Severe NPDR:</bold> fulfilling one rule of the 4-2-1 rule.
<list list-type="bullet"><list-item><p><bold>4-2-1 rule</bold>
<list list-type="bullet"><list-item><p>Severe hemorrhages in all four quadrants</p></list-item><list-item><p>Venous beading in 2 or more quadrants</p></list-item><list-item><p>Moderate IRMA in 1 or more quadrants</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Very Severe NPDR:</bold> fulfilling two or more rules of the 4-2-1 rule.<xref ref-type="bibr" rid="article-28462.r36">[36]</xref><xref ref-type="bibr" rid="article-28462.r37">[37]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Proliferative Diabetic&#x000a0;Retinopathy </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mild to moderate PDR-&#x000a0;</bold>NVD or NVE insufficient to meet high-risk characteristics</p>
          </list-item>
          <list-item>
            <p><bold>High-risk PDR- </bold>
<list list-type="bullet"><list-item><p>NVD greater than ETDRS standard photograph 10A (about 1/3 disc area).</p></list-item><list-item><p>Any NVD with vitreous hemorrhage.</p></list-item><list-item><p>NVE greater than 1/2 disc area with vitreous hemorrhage.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Advanced Diabetic Eye Disease </bold>is the end-stage vision-threatening complication of diabetic retinopathy in patients whose treatment is inadequate or unsuccessful. It may present as pre-retinal or intragel hemorrhage, tractional retinal detachment, or rubeosis iridis.&#x000a0;</p>
        <p><bold>Diabetic Macular Edema&#x000a0;(DME)</bold>&#x000a0;can be classified into the following groups&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Focal exudative and diffuse maculopathy</p>
          </list-item>
          <list-item>
            <p>Ischemic and non-ischemic maculopathy</p>
          </list-item>
          <list-item>
            <p>Tractional and non-tractional maculopathy</p>
          </list-item>
          <list-item>
            <p>Center involving macular edema and non-center involving macular edema</p>
          </list-item>
        </list>
        <p>
<bold>ETDRS Definition of Clinically Significant Macular Edema (CSME)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Retinal edema within 500 &#x000b5;m of the center of the fovea</p>
          </list-item>
          <list-item>
            <p>Hard exudates within 500 &#x000b5;m of the center of the fovea if associated with adjacent retinal thickening (which may be outside the 500 &#x000b5;m limit)</p>
          </list-item>
          <list-item>
            <p>Retinal edema one disc area (1500 &#x000b5;m) or larger, any part of which is within one disc diameter of the center of the fovea<xref ref-type="bibr" rid="article-28462.r38">[38]</xref><xref ref-type="bibr" rid="article-28462.r39">[39]</xref></p>
          </list-item>
        </list>
        <p>
<bold>OCT (optical coherence tomography) Classification of Diabetic Macular Edema</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sponge-like thickening of retinal layers</p>
          </list-item>
          <list-item>
            <p>Large cystoid spaces</p>
          </list-item>
          <list-item>
            <p>Serous detachment of the retina</p>
          </list-item>
          <list-item>
            <p>Tractional detachment of the fovea or vitreomacular traction</p>
          </list-item>
          <list-item>
            <p>Taut posterior hyaloid membrane.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>International Clinical Diabetic Retinopathy Disease Severity Scale&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold><italic toggle="yes">No apparent retinopathy</italic></bold>-No abnormality</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Mild NPDR</italic></bold>- Microaneurysms only</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Moderate NPDR</italic></bold> -More than just microaneurysms and less than severe disease</p>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">Severe NPDR</italic></bold> -No signs of PDR and any of the following:</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>20 intraretinal hemorrhages in each of the four quadrants</p>
              </list-item>
              <list-item>
                <p>Venous beading in &#x02265;2 quadrants</p>
              </list-item>
              <list-item>
                <p>Prominent IRMA &#x02265;1 quadrant</p>
              </list-item>
            </list>
          </list-item>
          <list-item>
            <p><bold><italic toggle="yes">PDR</italic></bold> - One or more of the following:&#x000a0;</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Neovascularization</p>
              </list-item>
              <list-item>
                <p>Vitreous or pre-retinal hemorrhage<xref ref-type="bibr" rid="article-28462.r40">[40]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>With regards to diabetic macular edema,&#x000a0;the DME may be:</p>
        <list list-type="bullet">
          <list-item>
            <p>'<bold>DME apparently absent</bold>'- Apparent retinal thickening and hard exudates at the posterior pole are absent.</p>
          </list-item>
          <list-item>
            <p>'<bold>DME apparently present</bold>'- There is some 'apparent&#x000a0;retinal thickening and hard exudates at the posterior pole.' It can further be classified into mild, moderate, and severe based on the distance of thickening and hard exudates from the center of the fovea.
<list list-type="bullet"><list-item><p><bold><italic toggle="yes">Mild DME</italic></bold>: The retinal thickening or hard exudates are located far from the center of the fovea.</p></list-item><list-item><p><bold><italic toggle="yes">Moderate DME</italic></bold>: Retinal thickening or hard exudates are approaching the center of the macula but not involving the center</p></list-item><list-item><p><bold><italic toggle="yes">Severe DME</italic></bold>: Hard exudate and thickening involve the center of the fovea.</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28462.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Laboratory Examination</bold>
</p>
        <p>The following are the diabetic markers&#x000a0;crucial for all the patients getting screened for diabetic retinopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fasting blood Glucose- The fasting blood glucose level of less than 110 mg/dl is normal. A fasting blood sugar (FBS) level of 110&#x000a0;to 125 mg/dl is prediabetes. In at least two samples, FBS of more than 126 mg/dl denotes diabetes.<xref ref-type="bibr" rid="article-28462.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p>HbA1C (glycosylated hemoglobin)- The normal range of HbA1c is between 4% to 5.6%. HbA1c level should be kept below 7%.</p>
          </list-item>
        </list>
        <p>Diabetes affects almost all the major organs of the body. Hence a thorough systemic examination should be done to rule out diabetic complications. Especially kidney function test, cardiac function test, liver function test, thyroid markers, blood pressure, and a neurological examination should be carried out. For this,&#x000a0;interprofessional collaboration is required.</p>
        <p>
<bold>Ocular Examination</bold>
</p>
        <p>On presentation, the patient should be thoroughly tested for:</p>
        <list list-type="bullet">
          <list-item>
            <p>Visual acuity,</p>
          </list-item>
          <list-item>
            <p>IOP (intraocular pressure) measurement,</p>
          </list-item>
          <list-item>
            <p>Gonioscopy (for neovascularization of iris/angles),</p>
          </list-item>
          <list-item>
            <p>Slit-lamp examination (to rule out other ocular manifestations of diabetes mellitus), and</p>
          </list-item>
          <list-item>
            <p>Dilated fundus examination with +78 or +90 D lens on slit lamp and with +20 or +28 D lens with an indirect ophthalmoscope&#x000a0;- the grading of diabetic retinopathy should be done</p>
          </list-item>
        </list>
        <p>Additional posterior segment investigations for the evaluation of diabetic retinopathy include:</p>
        <p>
<bold>Fundus Photography</bold>
</p>
        <p>Color fundus photographs are taken&#x000a0;in the instances listed below.<xref ref-type="bibr" rid="article-28462.r42">[42]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Documentation and record purposes</p>
          </list-item>
          <list-item>
            <p>Patient education with counseling</p>
          </list-item>
        </list>
        <p>The standard seven fields of modified Airlie House classification should be taken (Figure).<xref ref-type="bibr" rid="article-28462.r36">[36]</xref><xref ref-type="bibr" rid="article-28462.r43">[43]</xref>&#x000a0;Each&#x000a0;image&#x000a0;has a 30-degree&#x000a0;field.&#x000a0;</p>
        <p>
<bold>Fundus Fluorescein Angiography (FFA)</bold>
</p>
        <p>FFA is indicated in the following situations.<xref ref-type="bibr" rid="article-28462.r35">[35]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>For the diagnosis of ischemic maculopathy</p>
          </list-item>
          <list-item>
            <p>To locate capillary dropout areas</p>
          </list-item>
          <list-item>
            <p>To differentiate IRMA from neovascularization</p>
          </list-item>
          <list-item>
            <p>To differentiate disc collaterals from disc neovascularization</p>
          </list-item>
          <list-item>
            <p>To reveal occult new vessels that could not be detected on clinical examination</p>
          </list-item>
          <list-item>
            <p>To find out the cause of unexplained visual loss</p>
          </list-item>
          <list-item>
            <p>To differentiate pseudophakic cystoid macular edema and diabetic macular edema</p>
          </list-item>
        </list>
        <p>
<bold>Ultrawide Field Fundus Imaging (UWFI) and Fundus Fluorescein Angiogram (UWFA)</bold>
</p>
        <p>UWFI and UWFA document the changes in the posterior segment in a single frame. Commercially available UWFI (at least a 100-degree field of view) includes Optos/California, Mirante, Clarus, Retcam, and Spectralis. UWFI using a scanning laser ophthalmoscope and ellipsoid mirror, captures images in small pupils and hazy media.<xref ref-type="bibr" rid="article-28462.r44">[44]</xref><xref ref-type="bibr" rid="article-28462.r45">[45]</xref>&#x000a0;Peripheral retinal capillary nonperfusion areas may be better delineated and planned for 'targeted retinal photocoagulation' in proliferative diabetic retinopathy&#x000a0;or diabetic macular edema.<xref ref-type="bibr" rid="article-28462.r46">[46]</xref><xref ref-type="bibr" rid="article-28462.r47">[47]</xref><xref ref-type="bibr" rid="article-28462.r48">[48]</xref>&#x000a0;Peripheral vascular changes may be more common in DR than was previously thought.</p>
        <p>
<bold>Optical Coherence Tomography (OCT)</bold>
</p>
        <p>OCT of the macula helps</p>
        <list list-type="bullet">
          <list-item>
            <p>To evaluate retinal thickening</p>
          </list-item>
          <list-item>
            <p>For the assessment and monitoring of edema after initiation of treatment, especially&#x000a0;to plan for the next sitting of intravitreal injections</p>
          </list-item>
          <list-item>
            <p>To diagnose vitreomacular traction (VMT) and the epiretinal membrane (ERM), which might require surgery (pars plans vitrectomy)</p>
          </list-item>
        </list>
        <p>
<bold>Ultrasonography (B Scan)</bold>
</p>
        <p>It is a very useful tool in hazy media&#x000a0;to evaluate</p>
        <list list-type="bullet">
          <list-item>
            <p>Vitreous hemorrhage</p>
          </list-item>
          <list-item>
            <p>Tractional retinal detachment</p>
          </list-item>
          <list-item>
            <p>Subhyaloid hemorrhage</p>
          </list-item>
          <list-item>
            <p>Posterior vitreous detachment</p>
          </list-item>
        </list>
        <p>
<bold>Optical Coherence Tomography Angiography (OCTA)</bold>
</p>
        <p>OCTA employs motion contrast imaging to retinal blood flow, generating images similar to fluorescein angiography without the need to inject the dye invasively.</p>
        <list list-type="bullet">
          <list-item>
            <p>It provides detailed information on the retinal vasculature</p>
          </list-item>
          <list-item>
            <p>It is helpful for the demarcation of the foveal avascular zone, helping to find out foveal ischemia</p>
          </list-item>
          <list-item>
            <p>It enables accurate detection of even mild IRMA</p>
          </list-item>
          <list-item>
            <p>It helps to delineate capillary dropout areas</p>
          </list-item>
        </list>
        <p>Vascular signs like looping, beading, and dilatation can very well be appreciated on OCTA. OCTA may help the earliest detection of microvascular changes (before the visibility of microaneurysm).<xref ref-type="bibr" rid="article-28462.r49">[49]</xref>&#x000a0;OCTA is especially useful in patients with kidney disease and patients prone to an anaphylactic reaction to the dyes.</p>
        <p>
<bold>Artificial Intelligence-based Devices</bold>
</p>
        <p>FDA has approved a software program&#x000a0;IDx-DR for the detection of 'more than mild diabetic retinopathy' or its absence in 2018. In 2020, EyeArt (Eyenuk) received FDA clearance for the autonomous detection of 'more than mild diabetic retinopathy and vision-threatening diabetic retinopathy.'</p>
      </sec>
      <sec id="article-28462.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>General Systemic Control of Diabetes</bold>
</p>
        <p>The systemic status should be optimized by</p>
        <list list-type="bullet">
          <list-item>
            <p>Strict metabolic control of diabetes,</p>
          </list-item>
          <list-item>
            <p>Maintaining HbA1C levels under 7%,</p>
          </list-item>
          <list-item>
            <p>Lifestyle modifications like routine exercises and a proper diabetic food diet,</p>
          </list-item>
        </list>
        <p>Patients should visit diabetologists for proper follow-up visits and take timely antidiabetic medications. Other systemic ailments like hypertension, dyslipidemia, hypoproteinemia, anemia, nephropathy, neuropathy, cardiac ailments, and others should also be taken care of by respective medications and excellent interprofessional collaboration.</p>
        <p>
<bold>Management of Non-Proliferative Diabetic Retinopathy (NPDR)</bold>
</p>
        <p>Strict glycemic control and strict compliance of patients towards antidiabetic medication is the key to managing a case of NPDR. Stress should be on proper systemic control of diabetes mellitus, keeping a watch on the progression of ocular findings. Associated comorbidities should be addressed. A detailed systemic investigation by a physician or an endocrinologist should be done to rule out any other systemic side-effects of diabetes mellitus.</p>
        <p>The suggested follow-up schedule is given.</p>
        <list list-type="bullet">
          <list-item>
            <p>Very mild NPDR- follow-up every year</p>
          </list-item>
          <list-item>
            <p>Mild to moderate NPDR - follow-up 6-12 monthly. Sixteen percent of cases of mild NPDR and 23% of cases of moderate NPDR progress to proliferative stages within four years<xref ref-type="bibr" rid="article-28462.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p>Severe to Very Severe NPDR- Close follow-up within 2-4 months. Fifty percent of severe NPDR and 75% of cases of very severe&#x000a0;NPDR progress to PDR within one year<xref ref-type="bibr" rid="article-28462.r40">[40]</xref><xref ref-type="bibr" rid="article-28462.r50">[50]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Management of Diabetic Macular Edema (DME)</bold>
</p>
        <p><bold>Center-involving diabetic macular edema</bold>- Nowadays, anti-VEGF agents have become the first line of treatment for center-involving diabetic macular edema. Bevacizumab, ranibizumab, and aflibercept have beneficial effects in patients with baseline better visual acuity. Aflibercept is shown to have better visual outcomes in patients with worse baseline visual acuity on presentation.<xref ref-type="bibr" rid="article-28462.r51">[51]</xref>&#x000a0;Recently, aflibercept and ranibizumab have received FDA approval for use in both DME and diabetic retinopathy.<xref ref-type="bibr" rid="article-28462.r52">[52]</xref>&#x000a0;Intravitreal steroid implants also are used in recalcitrant cases.<xref ref-type="bibr" rid="article-28462.r53">[53]</xref>&#x000a0;</p>
        <p><bold>Non-center involving macular edema</bold>&#x000a0;- Focal or Grid laser-guided by ETDRS is the treatment of choice.</p>
        <p>Nowadays, in the era of Anti-VEGF medications, laser treatment is usually avoided in the center involving macular edema. It may be added as adjuvant therapy in patients not responding to anti-VEGF therapy alone. As stated by ETDRS, laser helped in halting the progression of moderate visual loss, but it did not improve the visual acuity. Bevacizumab intravitreal injection is also effective in the center-involving DME, but it is not FDA approved. Hence it is available only for off-label use. Cluster endophthalmitis due to fake drugs or other reasons is another concern.<xref ref-type="bibr" rid="article-28462.r54">[54]</xref>&#x000a0;DRCR (diabetic retinopathy clinical research) network studied the role of aflibercept in DME, and it was found to be useful in patients with initial worse visual acuity (Protocol T of DRCR.net).<xref ref-type="bibr" rid="article-28462.r51">[51]</xref>&#x000a0;Other notable studies other than the DRCR network on intravitreal Anti-VEGF injections included RISE, RIDE, READ, RESTORE, BOLT, and RESOLVE.&#x000a0;</p>
        <p>Doses of commonly used intravitreal injections:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Bevacizumab- 1.25mg/0.05 ml (PACORES, DRCR.net PROTOCOL H, BOLT, READ-2)<xref ref-type="bibr" rid="article-28462.r55">[55]</xref><xref ref-type="bibr" rid="article-28462.r56">[56]</xref><xref ref-type="bibr" rid="article-28462.r57">[57]</xref><xref ref-type="bibr" rid="article-28462.r58">[58]</xref><xref ref-type="bibr" rid="article-28462.r59">[59]</xref></p>
          </list-item>
          <list-item>
            <p>Ranibizumab - 0.5 mg or 0.3 mg /0.05 ml(RESOLVE, DRCR.net PROTOCOL I, RESTORE, RISE/RIDE<xref ref-type="bibr" rid="article-28462.r60">[60]</xref><xref ref-type="bibr" rid="article-28462.r61">[61]</xref>)<xref ref-type="bibr" rid="article-28462.r62">[62]</xref><xref ref-type="bibr" rid="article-28462.r63">[63]</xref><xref ref-type="bibr" rid="article-28462.r64">[64]</xref></p>
          </list-item>
          <list-item>
            <p>Aflibercept -2 mg/0.05 ml (DA VINCI, VISTA/VIVID, DRCR.net PROTOCOL T)<xref ref-type="bibr" rid="article-28462.r65">[65]</xref><xref ref-type="bibr" rid="article-28462.r66">[66]</xref><xref ref-type="bibr" rid="article-28462.r67">[67]</xref></p>
          </list-item>
          <list-item>
            <p>Pegaptanib- 0.3mg/&#x000a0;0.09 ml (not FDA approved for this indication)<xref ref-type="bibr" rid="article-28462.r68">[68]</xref><xref ref-type="bibr" rid="article-28462.r69">[69]</xref></p>
          </list-item>
          <list-item>
            <p>Brolucizumab 6mg/0.05 ml (not approved by FDA for this indication as of May 2022)<xref ref-type="bibr" rid="article-28462.r70">[70]</xref></p>
          </list-item>
        </list>
        <p>Long-acting corticosteroid implants like dexamethasone implants and fluocinolone acetonide implants (Retisert and Iluvien) are also used in diabetic macular edema. Though they are not considered the first line of treatment. They are reserved for cases not responding to multiple injections of Anti-VEGF medications&#x000a0;(according to protocol U of DRCR.net).<xref ref-type="bibr" rid="article-28462.r71">[71]</xref>&#x000a0;Their main advantage is long-term control of inflammation and a lesser frequency of administration. The high cost is also one of the factors for its limited use. Intravitreal injections of triamcinolone are not FDA approved, have poorer results, and are linked with more complications than anti-VEGF medications. Glaucoma is a significant side effect of intravitreal steroids.&#x000a0;A new port-delivery system for sustained release of ranibizumab, has been approved to manage wet age-related macular degeneration by the FDA in 2021.&#x000a0;Its&#x000a0;promises to be a new therapy for DME.</p>
        <p><bold>Tractional diabetic macular edema</bold>&#x000a0;can occur because of VMT (vitreomacular traction) or ERM (epiretinal membrane). Vitrectomy surgery should be considered in such cases. Intravitreal injections might worsen the traction component.&#x000a0;Laser spots, too, should be given away from the tractional area to avoid further worsening.&#x000a0;</p>
        <p><bold>Refractory Diabetic macular edema</bold>- The definition of refractory or persistent DME varies, including macular edema not responding to multiple injections of anti-VEGF and, at least one sitting of laser, and suboptimal response (central macular thickness on OCT of more than 250 microns with associated visual loss) to 6 consecutive monthly injections of anti-VEGF agents.<xref ref-type="bibr" rid="article-28462.r72">[72]</xref><xref ref-type="bibr" rid="article-28462.r73">[73]</xref>&#x000a0;A possible approach to such cases includes evaluating systemic control, higher dosing or frequency of anti-VEGF medications, use of steroid implants (according to protocol U of DRCR.net), rechecking of the diagnosis, ruling out any unfavorable anatomical causes, and ultrawide field angiography to look for extreme peripheral ischemic areas and to laser as far in the periphery as possible.<xref ref-type="bibr" rid="article-28462.r74">[74]</xref><xref ref-type="bibr" rid="article-28462.r71">[71]</xref><xref ref-type="bibr" rid="article-28462.r75">[75]</xref></p>
        <p><bold>Ischemic type of diabetic macular edema</bold>&#x000a0;is associated with poor visual prognosis.&#x000a0;The patient can be considered for an extreme peripheral laser to kill out the ischemic areas responsible for VEGF release.<xref ref-type="bibr" rid="article-28462.r76">[76]</xref>&#x000a0;Steroid implants could be tried. However, the prognosis is guarded despite all the measures.<xref ref-type="bibr" rid="article-28462.r77">[77]</xref></p>
        <p>
<bold>Treatment of Proliferative Diabetic Retinopathy (PDR)</bold>
</p>
        <p>Panretinal photocoagulation (PRP) has been considered the standard treatment of proliferative diabetic retinopathy for ages. But because of its destructive properties, intense research was done to find an alternative non-destructive mode of management of diabetic retinopathy. Various studies evaluated the role of intravitreal anti-VEGF injections in PDR cases. Because of the limited half-life of these injections, repeated injections at timely intervals become mandatory. Hence cost-effectivity of this regime is questionable. A concoction of intravitreal injection and pan-retinal photocoagulation, depending on the severity of the disease and taking into account the presence or absence of macular edema, may help manage diabetic retinopathy patients.<xref ref-type="bibr" rid="article-28462.r78">[78]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Non-high-risk PDR without DME - Careful 2&#x000a0;to 4 monthly follow-up and immediate pan-retinal photocoagulation should be done if high-risk PDR occurs. Some physicians perform PRP in all PDR cases.</p>
          </list-item>
          <list-item>
            <p>High-risk PDR without macular edema- Pan-retinal photocoagulation should be initiated.<xref ref-type="bibr" rid="article-28462.r79">[79]</xref></p>
          </list-item>
          <list-item>
            <p>PDR with DME- Combined intravitreal anti-VEGF injections and PRP sessions should be considered.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>High-risk PDR in which complete photocoagulation is not possible- Alternatives like cryopexy or vitrectomy should be considered.<xref ref-type="bibr" rid="article-28462.r79">[79]</xref></p>
          </list-item>
        </list>
        <p>In Protocol S of DRCR.net, a comparison of safety and efficacy of PRP to intravitreal injection of 0.5 mg ranibizumab was studied. The primary outcome of protocol S ranibizumab 0.5 mg was non-inferior to PRP. Hence, ranibizumab&#x000a0;might compete with PRP to be the first line of management in the near future. High cost, repeated injection, multiple follow-up visits, distortion of the vitreous anatomy and physiology because of the repeated injections, chances of endophthalmitis, and tachyphylaxis are hindering factors.<xref ref-type="bibr" rid="article-28462.r80">[80]</xref></p>
        <p>
<bold>Treatment of Advanced Diabetic Eye Disease</bold>
</p>
        <p>Prognosis is guarded in patients with advanced diabetic eye disease. Persistent vitreous hemorrhage can initially be given the trial of observation or intravitreal injection of the anti-VEGF agent, following which, if the hemorrhage resolves, then scattered pan-retinal photocoagulation in the visible areas can be tried.<xref ref-type="bibr" rid="article-28462.r81">[81]</xref>&#x000a0;Ultrasnogram must exclude retinal traction if such an approach is considered.</p>
        <p>If the hemorrhage does not resolve with the above management, pars plana vitrectomy should be considered. Also, vitrectomy is the treatment of choice in cases presenting with tractional retinal detachment.</p>
        <p>Indications of vitrectomy in diabetic patients include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-clearing vitreous hemorrhage (vitreous/subhyaloid/pre-macular)</p>
          </list-item>
          <list-item>
            <p>Tractional retinal detachment with macula off</p>
          </list-item>
          <list-item>
            <p>Combined tractional with rhegmatogenous retinal detachment</p>
          </list-item>
          <list-item>
            <p>Anterior segment neovascularization with the invisibility of the posterior segment</p>
          </list-item>
          <list-item>
            <p>Ghost cell glaucoma</p>
          </list-item>
          <list-item>
            <p>Thick epiretinal membrane</p>
          </list-item>
          <list-item>
            <p>Vitreomacular traction</p>
          </list-item>
        </list>
        <p>In vitrectomy surgery, three pars plana ports are made, one for the infusion line, one for the light pipe, and the third for the microinstruments. A fourth port can be made if a chandelier light source is used in cases of bimanual vitrectomy.<xref ref-type="bibr" rid="article-28462.r82">[82]</xref>&#x000a0;Core vitrectomy is done. Meticulous separation of posterior vitreous from the retina is tried with the use of triamcinolone.&#x000a0;The fibrovascular proliferation at the optic disc should be trimmed as pulling it off may cause massive intraocular hemorrhage and is not recommended.&#x000a0;Tractional components are managed by segmentation or delamination.<xref ref-type="bibr" rid="article-28462.r83">[83]</xref>&#x000a0;All bleeders are cauterized.&#x000a0;Fluid- Air exchange is done. If required, ERM peeling with or without ILM (internal limiting membrane) peeling is done with due precautions. Pan-retinal endophotocoagulation is done. At the end of the surgery, tamponade in the form of air, fluid, gases (C3F8, SF6), or silicone oil, can be injected.</p>
        <p>In cases of rubeosis iridis, pan-retinal photocoagulation with or without anti-VEGF medication might be helpful in the early phases. In the advanced stages, the new vessels lead to fibrosis and contracture, leading to permanent distortion of the angles&#x000a0;causing&#x000a0;refractory glaucoma, which might eventually require a glaucoma drainage implant). The prognosis is, however, poor in such cases. Painful blind eyes may need diode laser cyclophotocoagulation or cyclocryotherapy.</p>
        <p>
<bold>Treatment of Diabetic Retinopathy (without DME)</bold>
</p>
        <p>This is an FDA-approved indication of ranibizumab and aflibercept, which can reduce the severity of diabetic retinopathy.</p>
      </sec>
      <sec id="article-28462.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of diabetic macular edema&#x000a0;includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertensive retinopathy&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Central retinal vein occlusion</p>
          </list-item>
          <list-item>
            <p>Branch retinal vein occlusion<xref ref-type="bibr" rid="article-28462.r84">[84]</xref></p>
          </list-item>
          <list-item>
            <p>Irvine Gass syndrome</p>
          </list-item>
          <list-item>
            <p>Post uveitic macular edema&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Ruptured microaneurysm<xref ref-type="bibr" rid="article-28462.r85">[85]</xref></p>
          </list-item>
          <list-item>
            <p>Macular edema secondary to epiretinal membrane</p>
          </list-item>
          <list-item>
            <p>Choroidal neovascular membrane.</p>
          </list-item>
        </list>
        <p>The diseases which can be mistaken as diabetic retinopathy based on the general fundus appearance include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Central retinal vein occlusion<xref ref-type="bibr" rid="article-28462.r86">[86]</xref></p>
          </list-item>
          <list-item>
            <p>Hypertensive retinopathy<xref ref-type="bibr" rid="article-28462.r87">[87]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Sickle cell retinopathy<xref ref-type="bibr" rid="article-28462.r88">[88]</xref></p>
          </list-item>
          <list-item>
            <p>Terson syndrome<xref ref-type="bibr" rid="article-28462.r89">[89]</xref><xref ref-type="bibr" rid="article-28462.r90">[90]</xref><xref ref-type="bibr" rid="article-28462.r89">[89]</xref></p>
          </list-item>
          <list-item>
            <p>Ocular ischemic syndrome<xref ref-type="bibr" rid="article-28462.r91">[91]</xref><xref ref-type="bibr" rid="article-28462.r92">[92]</xref><xref ref-type="bibr" rid="article-28462.r91">[91]</xref></p>
          </list-item>
          <list-item>
            <p>Branch retinal vein occlusion<xref ref-type="bibr" rid="article-28462.r93">[93]</xref></p>
          </list-item>
          <list-item>
            <p>Hemiretinal vein occlusion<xref ref-type="bibr" rid="article-28462.r94">[94]</xref></p>
          </list-item>
          <list-item>
            <p>Valsalva retinopathy<xref ref-type="bibr" rid="article-28462.r95">[95]</xref></p>
          </list-item>
          <list-item>
            <p>Post-traumatic retinal bleed<xref ref-type="bibr" rid="article-28462.r96">[96]</xref></p>
          </list-item>
          <list-item>
            <p>Retinal macroaneurysm<xref ref-type="bibr" rid="article-28462.r97">[97]</xref></p>
          </list-item>
          <list-item>
            <p>Retinopathy in thalassemia<xref ref-type="bibr" rid="article-28462.r98">[98]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28462.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of diabetic retinopathy depends on the duration of diabetes, glycemic control, associated comorbid conditions, and patient compliance to the appropriate line of treatment.<xref ref-type="bibr" rid="article-28462.r99">[99]</xref><xref ref-type="bibr" rid="article-28462.r100">[100]</xref>&#x000a0;Proper patient counseling is needed about their retinal condition and making patients aware that delay in proper follow-up could lead to permanent, irreversible vision loss. The initial stages of diabetic retinopathy are reversible if proper glycemic control is achieved. Many patients with diabetic macular edema require long-term support of repeated injections of intravitreal anti-VEGF medications. Patients treated with pan-retinal photocoagulation may require additional supplementation of anti-VEGF medications if there is persistent macular edema and neovascularization. Once there is tractional macular detachment for a longer duration, the visual prognosis is usually guarded as the macular anatomy is markedly distorted.</p>
        <p>OCT biomarkers of prognosis of diabetic retinopathy include refractile bodies, disorganization of inner layers of the retina (DRIL), disruption of outer layers of the retina (DORL), choroidal thickness, epiretinal membrane, vitreomacular adhesions, subretinal fluid, macular thickness, and integrity of ellipsoid zone.<xref ref-type="bibr" rid="article-28462.r42">[42]</xref><xref ref-type="bibr" rid="article-28462.r101">[101]</xref></p>
      </sec>
      <sec id="article-28462.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Vision-threatening complications associated with poorly controlled diabetic retinopathy include diabetic macular edema, tractional retinal detachment, and vitreous hemorrhage<xref ref-type="bibr" rid="article-28462.r102">[102]</xref> as a late sequela of proliferative diabetic retinopathy.<xref ref-type="bibr" rid="article-28462.r103">[103]</xref><xref ref-type="bibr" rid="article-28462.r104">[104]</xref></p>
        <p>Management of Diabetic retinopathy with anti-VEGF therapy, laser photocoagulation, or vitrectomy surgery is also not free of complications.</p>
        <p>
<bold>Complications Related to Anti-VEGF Medications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>IOP spike</p>
          </list-item>
          <list-item>
            <p>Cataract formation</p>
          </list-item>
          <list-item>
            <p>Iatrogenic retinal/posterior capsular tear&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Vitreous hemorrhage</p>
          </list-item>
          <list-item>
            <p>Rhegmatogenous Retinal detachment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Worsening of traction over the macula if given in patients with tractional retinal detachment&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Endophthalmitis</p>
          </list-item>
        </list>
        <p>
<bold>Complications Related to Laser Photocoagulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Vitreous hemorrhage</p>
          </list-item>
          <list-item>
            <p>Exudative retinal detachment and choroidal detachment if too many laser shots are given in a single sitting</p>
          </list-item>
          <list-item>
            <p>Reduction of contrast sensitivity, peripheral vision, and night vision after pan-retinal photocoagulation</p>
          </list-item>
          <list-item>
            <p>Permanent scotomas in the visual field</p>
          </list-item>
          <list-item>
            <p>Worsening of preexisting macular edema or development of macular edema after laser/PRP</p>
          </list-item>
          <list-item>
            <p>Chances of worsening optic disc pallor&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Complications Related to Vitrectomy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cataract formation</p>
          </list-item>
          <list-item>
            <p>IOP spike because of gas or oil tamponade</p>
          </list-item>
          <list-item>
            <p>Iatrogenic secondary tears leading to rhegmatogenous retinal detachment</p>
          </list-item>
          <list-item>
            <p>In chronic macular edema, the macular roof is very thin, so there are chances of deroofing at the macular region leading to a macular hole</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28462.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Laser photocoagulation is performed as an OPD (outpatient department) procedure. Maintaining proper glycemic control and taking care of other associated systemic illnesses are necessary. There are chances of worsening macular edema and moderate vision reduction after pan-retinal photocoagulation (PRP). If that happens, the patient&#x000a0;should report to the retinal surgeon for documentation and for planning a further line of management.</p>
        <p>It is common to have an acute spike of IOP after intravitreal injections for a few hours. It usually returns to normal within 3-6 hours.&#x000a0;It may be prudent to&#x000a0;routinely use a single tablet of acetazolamide 250 mg stat after intravitreal injection. After intravitreal injections, patients should be called for follow-up the next day; then, according to the stability of the ocular condition, follow-up at regular intervals should be planned. Sequential OCT and/or OCTA parameters are assessed in each follow-up visit, and depending on their findings, further management with repeat injections, observation, and/or switching to laser /vitrectomy surgery is planned.&#x000a0;</p>
        <p>
<bold>Post-operative Care</bold>
</p>
        <p>After surgery, the eye is patched.&#x000a0;After the patch is removed, the eye is cleaned, and topical administration of medications like antibiotics with steroid eye drops and cycloplegic eye drops are started. After injecting gases like sf6/c3f8 or silicone oil, there are chances of IOP rise post-operatively, which needs to be managed with appropriate antiglaucoma medications. Patients can then be called for regular, timely follow-ups to screen their post-operative outcomes. If silicone oil tamponade is done, the patient should be explained the need for a mandatory second surgery to remove oil.</p>
      </sec>
      <sec id="article-28462.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>The American Academy of Ophthalmology's current recommendation states that people with diabetes mellitus type 1 should have yearly screening for diabetic retinopathy starting five years after the onset of diabetes. Patients with diabetes mellitus type 2 should have fundus evaluation at the time of diagnosis and annually<bold>&#x000a0;</bold>thereafter.<xref ref-type="bibr" rid="article-28462.r105">[105]</xref><xref ref-type="bibr" rid="article-28462.r106">[106]</xref>&#x000a0;</p>
        <p>The patient should be counseled properly regarding the prognosis of diabetic retinopathy. Early diagnosis, management, and follow-up visits at timely intervals depending on the stage of presentation of diabetic retinopathy are mandatory. Systemic dysregulation of diabetes can lead to an exponential worsening of diabetic retinopathy. Lifestyle modification should be done along with proper systemic and topical medications to halt the progression of diabetic retinopathy.</p>
      </sec>
      <sec id="article-28462.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Any patient presenting with diabetic retinopathy should not receive treatment from an ophthalmologist in isolation. It requires a multispecialty evaluation by an endocrinologist, nephrologist, cardiologist, and neurologist. Interprofessional communication can lead to better patient management. The patient most often presents to the primary health care provider or nurse practitioner, and these professionals should be aware of the condition as it is treatable. Prompt referral to an ophthalmologist is necessary. These patients can then be followed by their primary clinicians and should ensure correct dosing on the medication management aspect of the condition.</p>
        <p>Nursing&#x000a0;is the first department to come in contact with the patients on follow-up. The nurse can assess the treatment progress, evaluate compliance with both medication and lifestyle measures, and report any issue to the primary care physician. This collaborative, interprofessional approach to care can ensure optimal patient outcomes.</p>
      </sec>
      <sec id="article-28462.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28462&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28462">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/diabetes/diabetic-retinopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28462">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28462/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28462">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28462.s17">
        <fig id="article-28462.image.f1" position="float" orientation="portrait">
          <caption>
            <p>diabetic retinopathy- neovascularisation of disc (NVD) Contributed by Unnati Shukla, MS,DNB,MNAMS,FVRS,PhD Scholar</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PDR__POKAR_HIRA_19700101_9077" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-28462.s18">
        <fig id="article-28462.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Standard seven fields of the modified Airlie House classification of diabetic retinopathy. Each image is of 30-degree. Field 1 is centered at the optic disc and field 2 is centered at the fovea. Contributed by Koushik Tripathy, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="modified__airlie__house" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28462.s19">
        <title>References</title>
        <ref id="article-28462.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisma</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dulle</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Fort</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Current knowledge on diabetic retinopathy from human donor tissues.</article-title>
            <source>World J Diabetes</source>
            <year>2015</year>
            <month>Mar</month>
            <day>15</day>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>312</fpage>
            <page-range>312-20</page-range>
            <pub-id pub-id-type="pmid">25789112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hendrick</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Kulshreshtha</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Retinopathy.</article-title>
            <source>Prim Care</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-64</page-range>
            <pub-id pub-id-type="pmid">26319349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Diabetes Control and Complications Trial Research Group</collab>
              <name>
                <surname>Nathan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Genuth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lachin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crofford</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rand</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Sep</month>
            <day>30</day>
            <volume>329</volume>
            <issue>14</issue>
            <fpage>977</fpage>
            <page-range>977-86</page-range>
            <pub-id pub-id-type="pmid">8366922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <article-title>Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.</article-title>
            <source>Lancet</source>
            <year>1998</year>
            <month>Sep</month>
            <day>12</day>
            <volume>352</volume>
            <issue>9131</issue>
            <fpage>837</fpage>
            <page-range>837-53</page-range>
            <pub-id pub-id-type="pmid">9742976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sayin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pekel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Ocular complications of diabetes mellitus.</article-title>
            <source>World J Diabetes</source>
            <year>2015</year>
            <month>Feb</month>
            <day>15</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>92</fpage>
            <page-range>92-108</page-range>
            <pub-id pub-id-type="pmid">25685281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vieira-Potter</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Karamichos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Ocular Complications of Diabetes and Therapeutic Approaches.</article-title>
            <source>Biomed Res Int</source>
            <year>2016</year>
            <volume>2016</volume>
            <fpage>3801570</fpage>
            <pub-id pub-id-type="pmid">27119078</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petropoulos</surname>
                <given-names>IN</given-names>
              </name>
              <name>
                <surname>Ponirakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Visual complications in diabetes mellitus: beyond retinopathy.</article-title>
            <source>Diabet Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>478</fpage>
            <page-range>478-484</page-range>
            <pub-id pub-id-type="pmid">27917530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nittala</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for proliferative diabetic retinopathy in a Latino American population.</article-title>
            <source>Retina</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>34</volume>
            <issue>8</issue>
            <fpage>1594</fpage>
            <page-range>1594-9</page-range>
            <pub-id pub-id-type="pmid">24662751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sjoelie</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rottiers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Veglio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>JH</given-names>
              </name>
              <collab>EURODIAB Prospective Complications Study Group</collab>
            </person-group>
            <article-title>Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study.</article-title>
            <source>Diabetologia</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>12</issue>
            <fpage>2203</fpage>
            <page-range>2203-9</page-range>
            <pub-id pub-id-type="pmid">11793022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>XX</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of and Risk Factors for Diabetic Retinopathy and Diabetic Macular Edema in Patients with Early- and Late-Onset Diabetes Mellitus.</article-title>
            <source>Ophthalmic Res</source>
            <year>2022</year>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-299</page-range>
            <pub-id pub-id-type="pmid">32353847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schreur</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>van Asten</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Weeda</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groenewoud</surname>
                <given-names>JMM</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Klaver</surname>
                <given-names>CCW</given-names>
              </name>
              <name>
                <surname>Jeroen Klevering</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for development and progression of diabetic retinopathy in Dutch patients with type 1 diabetes mellitus.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>96</volume>
            <issue>5</issue>
            <fpage>459</fpage>
            <page-range>459-464</page-range>
            <pub-id pub-id-type="pmid">30188024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson-Berka</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Update on the treatment of diabetic retinopathy.</article-title>
            <source>ScientificWorldJournal</source>
            <year>2008</year>
            <month>Feb</month>
            <day>06</day>
            <volume>8</volume>
            <fpage>98</fpage>
            <page-range>98-120</page-range>
            <pub-id pub-id-type="pmid">18264628</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moutray</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lois</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Azuara-Blanco</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Different lasers and techniques for proliferative diabetic retinopathy.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>15</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD012314</fpage>
            <pub-id pub-id-type="pmid">29543992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arevalo</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Surgical management of diabetic retinopathy.</article-title>
            <source>Middle East Afr J Ophthalmol</source>
            <year>2013</year>
            <season>Oct-Dec</season>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>283</fpage>
            <page-range>283-92</page-range>
            <pub-id pub-id-type="pmid">24339677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kotwani</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy.</article-title>
            <source>Pharmacol Res</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>99</volume>
            <fpage>137</fpage>
            <page-range>137-48</page-range>
            <pub-id pub-id-type="pmid">26054568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kador</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Wyman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Aldose reductase, ocular diabetic complications and the development of topical Kinostat(&#x000ae;).</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>54</volume>
            <fpage>1</fpage>
            <page-range>1-29</page-range>
            <pub-id pub-id-type="pmid">27102270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kern</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Antonetti</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>LEH</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research.</article-title>
            <source>Ophthalmic Res</source>
            <year>2019</year>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>196</fpage>
            <page-range>196-202</page-range>
            <pub-id pub-id-type="pmid">31362288</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>ACY</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Retinopathy: Pathophysiology and Treatments.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Jun</month>
            <day>20</day>
            <volume>19</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">29925789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coughlin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Feenstra</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>M&#x000fc;ller cells and diabetic retinopathy.</article-title>
            <source>Vision Res</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>139</volume>
            <fpage>93</fpage>
            <page-range>93-100</page-range>
            <pub-id pub-id-type="pmid">28866025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>McVicar</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Berner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pringle</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uchida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brockbank</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Stitt</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>M&#x000fc;ller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products.</article-title>
            <source>Diabetologia</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>690</fpage>
            <page-range>690-8</page-range>
            <pub-id pub-id-type="pmid">21116609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pannicke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iandiev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wurm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Uckermann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>vom Hagen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reichenbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wiedemann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hammes</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Bringmann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina.</article-title>
            <source>Diabetes</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>633</fpage>
            <page-range>633-9</page-range>
            <pub-id pub-id-type="pmid">16505225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vujosevic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Midena</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and M&#x000fc;ller cells alterations.</article-title>
            <source>J Diabetes Res</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>905058</fpage>
            <pub-id pub-id-type="pmid">23841106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of diabetic retinopathy: old concepts and new questions.</article-title>
            <source>Eye (Lond)</source>
            <year>2002</year>
            <month>May</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>242</fpage>
            <page-range>242-60</page-range>
            <pub-id pub-id-type="pmid">12032713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Duh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gehlbach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pearlman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Zack</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ettyreddy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brough</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Campochiaro</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization.</article-title>
            <source>J Cell Physiol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-63</page-range>
            <pub-id pub-id-type="pmid">11424092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freyberger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;cker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yakut</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hammer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Effert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schifferdecker</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Derwahl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy.</article-title>
            <source>Exp Clin Endocrinol Diabetes</source>
            <year>2000</year>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>106</fpage>
            <page-range>106-9</page-range>
            <pub-id pub-id-type="pmid">10826517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maglione</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ribatti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morbidelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lago</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Battisti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paoletti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parise</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vincenti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Viglietto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Persico</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic.</article-title>
            <source>Lab Invest</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>76</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-31</page-range>
            <pub-id pub-id-type="pmid">9111514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vincent</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia.</article-title>
            <source>Diabetes</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>224</fpage>
            <page-range>224-30</page-range>
            <pub-id pub-id-type="pmid">17192486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lei</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>EPO attenuates inflammatory cytokines by Muller cells in diabetic retinopathy.</article-title>
            <source>Front Biosci (Elite Ed)</source>
            <year>2011</year>
            <month>Jan</month>
            <day>01</day>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>201</fpage>
            <page-range>201-11</page-range>
            <pub-id pub-id-type="pmid">21196299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of diabetic retinopathy in man.</article-title>
            <source>Eye (Lond)</source>
            <year>1993</year>
            <volume>7 ( Pt 2)</volume>
            <fpage>250</fpage>
            <page-range>250-3</page-range>
            <pub-id pub-id-type="pmid">7607344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cr&#x00103;i&#x00163;oiu</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[The morphopathological aspects of diabetic retinopathy].</article-title>
            <source>Oftalmologia</source>
            <year>1992</year>
            <season>Apr-Jun</season>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-8</page-range>
            <pub-id pub-id-type="pmid">1525142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pannicke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iandiev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Uckermann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Biedermann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kutzera</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wiedemann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wolburg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Reichenbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bringmann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A potassium channel-linked mechanism of glial cell swelling in the postischemic retina.</article-title>
            <source>Mol Cell Neurosci</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-502</page-range>
            <pub-id pub-id-type="pmid">15276152</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reichenbach</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wurm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pannicke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iandiev</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wiedemann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bringmann</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>M&#x000fc;ller cells as players in retinal degeneration and edema.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2007</year>
            <month>May</month>
            <volume>245</volume>
            <issue>5</issue>
            <fpage>627</fpage>
            <page-range>627-36</page-range>
            <pub-id pub-id-type="pmid">17219109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanski</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Diabetic retinopathy--a preventable cause of blindness.</article-title>
            <source>Practitioner</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>229</volume>
            <issue>1402</issue>
            <fpage>343</fpage>
            <page-range>343-8</page-range>
            <pub-id pub-id-type="pmid">3991450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ezra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keinan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mandel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Nahmias</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Non-dimensional analysis of retinal microaneurysms: critical threshold for treatment.</article-title>
            <source>Integr Biol (Camb)</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>474</fpage>
            <page-range>474-80</page-range>
            <pub-id pub-id-type="pmid">23371018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ruia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Fluorescein Angiography</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <article-title>Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.</article-title>
            <source>Ophthalmology</source>
            <year>1991</year>
            <month>May</month>
            <volume>98</volume>
            <issue>5 Suppl</issue>
            <fpage>786</fpage>
            <page-range>786-806</page-range>
            <pub-id pub-id-type="pmid">2062513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <article-title>Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group.</article-title>
            <source>Ophthalmology</source>
            <year>1991</year>
            <month>May</month>
            <volume>98</volume>
            <issue>5 Suppl</issue>
            <fpage>807</fpage>
            <page-range>807-22</page-range>
            <pub-id pub-id-type="pmid">2062514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>R</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gogia</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in management of diabetic macular edema.</article-title>
            <source>Curr Diabetes Rev</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-97</page-range>
            <pub-id pub-id-type="pmid">25801496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jorge</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Jorge</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Botelho</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Farat</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Virgili</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>El Dib</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Monotherapy laser photocoagulation for diabetic macular oedema.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>CD010859</fpage>
            <pub-id pub-id-type="pmid">30320466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilkinson</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Agardh</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dills</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kampik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pararajasegaram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verdaguer</surname>
                <given-names>JT</given-names>
              </name>
              <collab>Global Diabetic Retinopathy Project Group</collab>
            </person-group>
            <article-title>Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales.</article-title>
            <source>Ophthalmology</source>
            <year>2003</year>
            <month>Sep</month>
            <volume>110</volume>
            <issue>9</issue>
            <fpage>1677</fpage>
            <page-range>1677-82</page-range>
            <pub-id pub-id-type="pmid">13129861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Fasting blood glucose levels in patients with different types of diseases.</article-title>
            <source>Prog Mol Biol Transl Sci</source>
            <year>2019</year>
            <volume>162</volume>
            <fpage>277</fpage>
            <page-range>277-292</page-range>
            <pub-id pub-id-type="pmid">30905457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Fawzi</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Imaging and Biomarkers in Diabetic Macular Edema and Diabetic Retinopathy.</article-title>
            <source>Curr Diab Rep</source>
            <year>2019</year>
            <month>Aug</month>
            <day>31</day>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">31473838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wadekar</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of rhegmatogenous retinal detachments using Optos ultrawide field fundus fluorescein angiography and comparison with ETDRS 7 field overlay.</article-title>
            <source>J Curr Ophthalmol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-267</page-range>
            <pub-id pub-id-type="pmid">30197958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Venkatesh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ultrawide Field Imaging in Uveitic Non-dilating Pupils.</article-title>
            <source>J Ophthalmic Vis Res</source>
            <year>2017</year>
            <season>Apr-Jun</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-233</page-range>
            <pub-id pub-id-type="pmid">28540019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vohra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the fundus in poorly dilating diabetic pupils using ultrawide field imaging.</article-title>
            <source>Clin Exp Optom</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>100</volume>
            <issue>6</issue>
            <fpage>735</fpage>
            <page-range>735-736</page-range>
            <pub-id pub-id-type="pmid">27704602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muqit</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Marcellino</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Henson</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Stanga</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2013</year>
            <month>May</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>251</fpage>
            <page-range>251-8</page-range>
            <pub-id pub-id-type="pmid">22176513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikkhah</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ghazi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Razzaghi</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Karimi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramezani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soheilian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial.</article-title>
            <source>Int Ophthalmol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>313</fpage>
            <page-range>313-321</page-range>
            <pub-id pub-id-type="pmid">28168567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Croft</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Wykoff</surname>
                <given-names>CC</given-names>
              </name>
              <collab>DAVE Study Group</collab>
            </person-group>
            <article-title>Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.</article-title>
            <source>Ophthalmology</source>
            <year>2018</year>
            <month>May</month>
            <volume>125</volume>
            <issue>5</issue>
            <fpage>683</fpage>
            <page-range>683-690</page-range>
            <pub-id pub-id-type="pmid">29336896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lajmi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hmaied</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Othmen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chelly</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>El Fekih</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Optical coherence tomography angiography microvascular changes in diabetics without diabetic retinopathy.</article-title>
            <source>Saudi J Ophthalmol</source>
            <year>2020</year>
            <season>Jul-Sep</season>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>156</fpage>
            <page-range>156-159</page-range>
            <pub-id pub-id-type="pmid">34085005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <article-title>Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group.</article-title>
            <source>Ophthalmology</source>
            <year>1991</year>
            <month>May</month>
            <volume>98</volume>
            <issue>5 Suppl</issue>
            <fpage>766</fpage>
            <page-range>766-85</page-range>
            <pub-id pub-id-type="pmid">2062512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>636</fpage>
            <page-range>636-643</page-range>
            <pub-id pub-id-type="pmid">28837425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaziri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Relhan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kishor</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Flynn</surname>
                <given-names>HW</given-names>
              </name>
            </person-group>
            <article-title>New Therapeutic Approaches in Diabetic Retinopathy.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2015</year>
            <season>Spring-Summer</season>
            <volume>12</volume>
            <issue>1-2</issue>
            <fpage>196</fpage>
            <page-range>196-210</page-range>
            <pub-id pub-id-type="pmid">26676668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lattanzio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cicinelli</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal Steroids in Diabetic Macular Edema.</article-title>
            <source>Dev Ophthalmol</source>
            <year>2017</year>
            <volume>60</volume>
            <fpage>78</fpage>
            <page-range>78-90</page-range>
            <pub-id pub-id-type="pmid">28427068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Intraocular use of bevacizumab in India: An issue resolved?</article-title>
            <source>Natl Med J India</source>
            <year>2017</year>
            <season>Nov-Dec</season>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>345</fpage>
            <page-range>345-347</page-range>
            <pub-id pub-id-type="pmid">30117450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stefanini</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Arevalo</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Maia</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab for the management of diabetic macular edema.</article-title>
            <source>World J Diabetes</source>
            <year>2013</year>
            <month>Apr</month>
            <day>15</day>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>19</fpage>
            <page-range>19-26</page-range>
            <pub-id pub-id-type="pmid">23593532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
              <name>
                <surname>Scott</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Greven</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Pieramici</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singerman</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Stockdale</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>114</volume>
            <issue>10</issue>
            <fpage>1860</fpage>
            <page-range>1860-7</page-range>
            <pub-id pub-id-type="pmid">17698196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Michaelides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaines</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Fraser-Bell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajendram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quhill</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boos</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bunce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hykin</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>1078</fpage>
            <page-range>1078-1086.e2</page-range>
            <pub-id pub-id-type="pmid">20416952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajendram</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Fraser-Bell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaines</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Michaelides</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Esposti</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bunce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Hykin</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3.</article-title>
            <source>Arch Ophthalmol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>130</volume>
            <issue>8</issue>
            <fpage>972</fpage>
            <page-range>972-9</page-range>
            <pub-id pub-id-type="pmid">22491395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Campochiaro</surname>
                <given-names>PA</given-names>
              </name>
              <collab>READ-2 Study Group</collab>
            </person-group>
            <article-title>Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study.</article-title>
            <source>Ophthalmology</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>116</volume>
            <issue>11</issue>
            <fpage>2175</fpage>
            <page-range>2175-81.e1</page-range>
            <pub-id pub-id-type="pmid">19700194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>JS</given-names>
              </name>
              <collab>RISE and RIDE Research Group</collab>
            </person-group>
            <article-title>Ranibizumab for diabetic macular edema. Author reply.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>221</fpage>
            <page-range>221-2</page-range>
            <pub-id pub-id-type="pmid">23283201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feiner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schlottmann</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Rundle</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Ehrlich</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>RIDE and RISE Research Group</collab>
            </person-group>
            <article-title>Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>120</volume>
            <issue>10</issue>
            <fpage>2013</fpage>
            <page-range>2013-22</page-range>
            <pub-id pub-id-type="pmid">23706949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sharp</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wolf-Schnurrbusch</surname>
                <given-names>UE</given-names>
              </name>
              <name>
                <surname>Gekkieva</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weichselberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study.</article-title>
            <source>Diabetes Care</source>
            <year>2010</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>2399</fpage>
            <page-range>2399-405</page-range>
            <pub-id pub-id-type="pmid">20980427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
              <name>
                <surname>Elman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Aiello</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Stockdale</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>117</volume>
            <issue>6</issue>
            <fpage>1064</fpage>
            <page-range>1064-1077.e35</page-range>
            <pub-id pub-id-type="pmid">20427088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Massin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schlingemann</surname>
                <given-names>RO</given-names>
              </name>
              <name>
                <surname>Sutter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Simader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gerstner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Weichselberger</surname>
                <given-names>A</given-names>
              </name>
              <collab>RESTORE study group</collab>
            </person-group>
            <article-title>The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>118</volume>
            <issue>4</issue>
            <fpage>615</fpage>
            <page-range>615-25</page-range>
            <pub-id pub-id-type="pmid">21459215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Do</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tolentino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ckert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sandbrink</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Beckmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>118</volume>
            <issue>9</issue>
            <fpage>1819</fpage>
            <page-range>1819-26</page-range>
            <pub-id pub-id-type="pmid">21546089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Schmidt-Erfurth</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Heier</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Midena</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Terasaki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>QD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Slakter</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Simader</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Soo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schmelter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yancopoulos</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berliner</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Zeitz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Metzig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Intravitreal aflibercept for diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>121</volume>
            <issue>11</issue>
            <fpage>2247</fpage>
            <page-range>2247-54</page-range>
            <pub-id pub-id-type="pmid">25012934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
              <name>
                <surname>Wells</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Ayala</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Aiello</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Antoszyk</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Arnold-Bush</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Melia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pieramici</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Mar</month>
            <day>26</day>
            <volume>372</volume>
            <issue>13</issue>
            <fpage>1193</fpage>
            <page-range>1193-203</page-range>
            <pub-id pub-id-type="pmid">25692915</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Adamis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Altaweel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aiello</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Goldbaum</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guyer</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SD</given-names>
              </name>
              <collab>Macugen Diabetic Retinopathy Study Group</collab>
            </person-group>
            <article-title>A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>112</volume>
            <issue>10</issue>
            <fpage>1747</fpage>
            <page-range>1747-57</page-range>
            <pub-id pub-id-type="pmid">16154196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultan</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Loftus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dombi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ice</surname>
                <given-names>KS</given-names>
              </name>
              <collab>Macugen 1013 Study Group</collab>
            </person-group>
            <article-title>A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.</article-title>
            <source>Ophthalmology</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>118</volume>
            <issue>6</issue>
            <fpage>1107</fpage>
            <page-range>1107-18</page-range>
            <pub-id pub-id-type="pmid">21529957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Emanuelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bandello</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barranco</surname>
                <given-names>JJE</given-names>
              </name>
              <name>
                <surname>Figueira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Souied</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ngah</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tuli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tadayoni</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dhoot</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bouillaud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kovacic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guerard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Garweg</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>238</volume>
            <fpage>157</fpage>
            <page-range>157-172</page-range>
            <pub-id pub-id-type="pmid">35038415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Bhavsar</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Melia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Punjabi</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Salehi-Had</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JK</given-names>
              </name>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
            </person-group>
            <article-title>Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-38</page-range>
            <pub-id pub-id-type="pmid">29127949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussain</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Ciulla</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2016</year>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-74</page-range>
            <pub-id pub-id-type="pmid">26674182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>SU</given-names>
              </name>
              <name>
                <surname>Maturi</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic Options in Refractory Diabetic Macular Oedema.</article-title>
            <source>Drugs</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>481</fpage>
            <page-range>481-492</page-range>
            <pub-id pub-id-type="pmid">28197794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Figueiredo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Babiuch</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boss</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Quantitative Ultra-Widefield Angiographic Features and Associations with Diabetic Macular Edema.</article-title>
            <source>Ophthalmol Retina</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-56</page-range>
            <pub-id pub-id-type="pmid">31690541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kuriakose</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Almeida</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of the Intravitreal Sustained-Release Dexamethasone Implant for Diabetic Macular Edema Refractory to Anti-Vascular Endothelial Growth Factor Therapy: Meta-Analysis and Clinical Implications.</article-title>
            <source>Ophthalmic Surg Lasers Imaging Retina</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-166</page-range>
            <pub-id pub-id-type="pmid">28195619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bresnick</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Diabetic macular edema. A review.</article-title>
            <source>Ophthalmology</source>
            <year>1986</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>7</issue>
            <fpage>989</fpage>
            <page-range>989-97</page-range>
            <pub-id pub-id-type="pmid">3531959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Usman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An Overview of Our Current Understanding of Diabetic Macular Ischemia (DMI).</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Jul</month>
            <day>30</day>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>e3064</fpage>
            <pub-id pub-id-type="pmid">30280060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Proliferative diabetic retinopathy.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2004</year>
            <season>Fall</season>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>69</fpage>
            <page-range>69-84</page-range>
            <pub-id pub-id-type="pmid">15577565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kansora</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Goldhardt</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Decision Making in Proliferative Diabetic Retinopathy Treatment.</article-title>
            <source>Curr Ophthalmol Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">31595210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Beaulieu</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Stockdale</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Flaxel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Shami</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
            </person-group>
            <article-title>Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-95</page-range>
            <pub-id pub-id-type="pmid">30096354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El Annan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Carvounis</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Current management of vitreous hemorrhage due to proliferative diabetic retinopathy.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2014</year>
            <season>Spring</season>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>141</fpage>
            <page-range>141-53</page-range>
            <pub-id pub-id-type="pmid">24613890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Rossmiller</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>PQ</given-names>
              </name>
            </person-group>
            <article-title>Four-port bimanual 23-gauge vitrectomy for diabetic tractional retinal detachment.</article-title>
            <source>Acta Ophthalmol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>365</fpage>
            <page-range>365-72</page-range>
            <pub-id pub-id-type="pmid">26855122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r83">
          <label>83</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mishra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Retinal Traction Detachment</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dysli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ckert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Munk</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Differentiation of Underlying Pathologies of Macular Edema Using Spectral Domain Optical Coherence Tomography (SD-OCT).</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2019</year>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>474</fpage>
            <page-range>474-483</page-range>
            <pub-id pub-id-type="pmid">31184556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r85">
          <label>85</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Singh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Retinal Macroaneurysm</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">35015432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r86">
          <label>86</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Blair</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Czyz</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <chapter-title>Central Retinal Vein Occlusion</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">30252241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r87">
          <label>87</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Modi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arsiwalla</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <chapter-title>Hypertensive Retinopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">30252236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonanomi</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Lavezzo</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell retinopathy: diagnosis and treatment.</article-title>
            <source>Arq Bras Oftalmol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>76</volume>
            <issue>5</issue>
            <fpage>320</fpage>
            <page-range>320-7</page-range>
            <pub-id pub-id-type="pmid">24232951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r89">
          <label>89</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanzino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wijdicks</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Flemming</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Terson's syndrome.</article-title>
            <source>Neurocrit Care</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>554</fpage>
            <page-range>554-8</page-range>
            <pub-id pub-id-type="pmid">21604080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r90">
          <label>90</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Dissociated optic nerve fiber layer in a case of Terson syndrome.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>NP11</fpage>
            <page-range>NP11-NP14</page-range>
            <pub-id pub-id-type="pmid">31155955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r91">
          <label>91</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terelak-Borys</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Skonieczna</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grabska-Liberek</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ocular ischemic syndrome - a systematic review.</article-title>
            <source>Med Sci Monit</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>RA138</fpage>
            <page-range>RA138-144</page-range>
            <pub-id pub-id-type="pmid">22847215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r92">
          <label>92</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazumdar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recurrent retinal and choroidal ischemia in a case of ocular ischemic syndrome.</article-title>
            <source>Ther Adv Ophthalmol</source>
            <year>2019</year>
            <season>Jan-Dec</season>
            <volume>11</volume>
            <fpage>2515841419848926</fpage>
            <pub-id pub-id-type="pmid">31321381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r93">
          <label>93</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cochran</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Mahabadi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Czyz</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <chapter-title>Branch Retinal Vein Occlusion</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30570991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r94">
          <label>94</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Figueroa</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Oden</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Blodi</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>VanVeldhuisen</surname>
                <given-names>PC</given-names>
              </name>
              <collab>SCORE2 Investigator Group</collab>
            </person-group>
            <article-title>SCORE2 Report 5: Vision-Related Function in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>184</volume>
            <fpage>147</fpage>
            <page-range>147-156</page-range>
            <pub-id pub-id-type="pmid">29074161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r95">
          <label>95</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Simakurthy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Valsalva Retinopathy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">31424803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r96">
          <label>96</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elyadari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Slassi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghanem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bekkay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zarrouki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mouine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benchakroun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berraho</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Case report of rare post-traumatic subretinal hemorrhage].</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2017</year>
            <month>May</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>e153</fpage>
            <page-range>e153-e156</page-range>
            <pub-id pub-id-type="pmid">28483155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r97">
          <label>97</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clemente-Tom&#x000e1;s</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gargallo-Benedicto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schilt-Catafal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Ibor</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Retinal arterial macroaneurysm: A study using optical coherence tomography and retinography.</article-title>
            <source>Arch Soc Esp Oftalmol (Engl Ed)</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>95</volume>
            <issue>2</issue>
            <fpage>e15</fpage>
            <page-range>e15-e16</page-range>
            <pub-id pub-id-type="pmid">31879142</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r98">
          <label>98</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heydarian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jafari</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dailami</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Hashemi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jafarzadehpour</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heirani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yekta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahjoob</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khabazkhoob</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies.</article-title>
            <source>Int Ophthalmol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>511</fpage>
            <page-range>511-527</page-range>
            <pub-id pub-id-type="pmid">31602527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r99">
          <label>99</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;nfeld</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Heidenkummer</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Kampik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in vitreous surgery for proliferative diabetic retinopathy.</article-title>
            <source>Ger J Ophthalmol</source>
            <year>1994</year>
            <month>May</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>137</fpage>
            <page-range>137-43</page-range>
            <pub-id pub-id-type="pmid">8038681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r100">
          <label>100</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Vigo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fandi&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cordido</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Prognostic factors in the treatment of edematous diabetic retinopathy with focal photocoagulation].</article-title>
            <source>Ophtalmologie</source>
            <year>1988</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>311</fpage>
            <page-range>311-4</page-range>
            <pub-id pub-id-type="pmid">3247197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r101">
          <label>101</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ac&#x000f3;n</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Multimodal Imaging in Diabetic Macular Edema.</article-title>
            <source>Asia Pac J Ophthalmol (Phila)</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <page-range>22-27</page-range>
            <pub-id pub-id-type="pmid">29376234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r102">
          <label>102</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tripathy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Vitreous Hemorrhage</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">32644557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r103">
          <label>103</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Browning</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Landers</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Current management of diabetic tractional retinal detachments.</article-title>
            <source>Indian J Ophthalmol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>1751</fpage>
            <page-range>1751-1762</page-range>
            <pub-id pub-id-type="pmid">30451175</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r104">
          <label>104</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gross</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Glassman</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Antoszyk</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Bressler</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Elman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Jampol</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Melia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stockdale</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>RW</given-names>
              </name>
              <collab>Diabetic Retinopathy Clinical Research Network</collab>
            </person-group>
            <article-title>Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>136</volume>
            <issue>10</issue>
            <fpage>1138</fpage>
            <page-range>1138-1148</page-range>
            <pub-id pub-id-type="pmid">30043039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r105">
          <label>105</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tseng</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Compliance with the American Academy of Ophthalmology Preferred Practice Pattern for Diabetic Retinopathy in a resident ophthalmology clinic.</article-title>
            <source>Retina</source>
            <year>2010</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>787</fpage>
            <page-range>787-94</page-range>
            <pub-id pub-id-type="pmid">20168268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28462.r106">
          <label>106</label>
          <element-citation publication-type="journal">
            <article-title>Screening guidelines for diabetic retinopathy. American College of Physicians, American Diabetes Association, and American Academy of Ophthalmology.</article-title>
            <source>Ann Intern Med</source>
            <year>1992</year>
            <month>Apr</month>
            <day>15</day>
            <volume>116</volume>
            <issue>8</issue>
            <fpage>683</fpage>
            <page-range>683-5</page-range>
            <pub-id pub-id-type="pmid">1546870</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
